Menu
Home

Manuscripts

June 19, 2024

The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer

NPJ Breast Cancer
Johnson KCC et al
Read More >
March 28, 2024

Seeking American Society of Clinical Oncology-Quality Oncology Practice Initiative (ASCO-QOPI) certification in a northern New England rural health system and cancer care network

Learning Health Systemas
Perrey HM et al
Read More >
January 10, 2024

Prognosis and conditional survival among women with newly diagnosed ovarian cancer

Gynecologic Oncology
Szamreta EA et al
Read More >
October 18, 2023

Natural history and real-world treatment outcomes for non-small cell lung cancer patients with EGFR exon 20 insertion mutation: An IASLC- ASCO CancerLinQ study

JTO Clinical & Research Reports
Behera M et al
Read More >
September 20, 2023

Real-world pitfalls of analyzing real-world data: A cautionary note and path forward

JCO Clinical Cancer Informatics
Cooper JD et al
Read More >
August 30, 2023

Prognostic impact of second primary malignancies in multiple myeloma: An ASCO CancerLinQ Discovery analysis of the modern era [CORRESPONDENCE]

American Journal of Hematology
Gibson S et al
Read More >
July 28, 2023

Multiple myeloma in adolescent and young adults: An ASCO CancerLinQ and SEER analysis

Clinical Lymphoma, Myeloma & Leukemia
Gibson S et al
Read More >
May 23, 2023

Health data sharing perspectives of patients receiving care in CancerLinQ-participating oncology practices

JCO Oncology Practice
Jagsi R et al
Read More >
March 26, 2023

Real-world big-data: Strengths and weaknesses of ASCO's CancerLinQ Discovery multiple myeloma dataset

American Journal of Hematology
DeStefano CB et al
Read More >

Abstracts

January 29, 2024

Patterns of concurrent chemotherapy selection in US patients undergoing trimodality therapy for muscle-invasive bladder cancer

ASCO Genitourinary Cancers Symposium 2024
Callihan E et al
Read More >
January 29, 2024

Real world evidence comparison of first-line (1L) immune-oncology(IO)/tyrosine kinase inhibitor (TKI) vs. IO/IO combination therapy in renal cell carcinoma (RCC)

ASCO Genitourinary Cancers Symposium 2024
Bolan P et al
Read More >
December 7, 2023

Disparities in genetic testing patterns and positivity among patients with breast cancer in the CancerLINQ real-world oncology database

San Antonio Breast Cancer Symposium 2023

Kantor O et al

Read More >
October 27, 2023

Uptake and efficacy of immuno-oncology combinations in metastatic renal cell carcinoma in the United States: Evidence from the ASCO CancerLinQ Discovery database

ASCO Quality Care Symposium 2023

Vento J et al

Read More >
October 27, 2023

Implementing a BRAF biomarker electronic clinical quality measure in CancerLinQ

ASCO Quality Care Symposium 2023

Drumheller C et al

Read More >
June 2, 2023

A real-world study of US patients with metastatic ovarian, fallopian tube, and peritoneal cancer (mOFPC) using integrated electronic health records (EHR) and claims datasets.

ASCO Annual Meeting 2023

Avinash P B et al

Read More >
June 2, 2023

Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer

ASCO Annual Meeting 2023

Naidoo J et al

Read More >
June 2, 2023

Electronic health record (EHR) and genomics-based machine learning (ML) to predict therapeutic effectiveness among patients with hormone-receptor positive (HR)+/HER2-advanced breast cancer (aBC)

ASCO Annual Meeting 2023

Hathi D et al

Read More >
June 2, 2023

Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets

ASCO Annual Meeting 2023

McKelvey B A et al

Read More >